Allogene Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing allogeneic chimeric antigen receptor T cell (AlloCAR T) therapies for cancer and autoimmune diseases. Unlike traditional autologous CAR T therapies that require custom manufacturing for each individual patient using their own cells, Allogene's business model centers on creating "off-the-shelf" treatments derived from healthy donors. This approach aims to provide readily available, on-demand cell therapies that can be manufactured reliably and at a larger scale, significantly reducing the time and cost associated with treatment. The company's pipeline includes several investigational candidates, such as ALLO-501A for large B-cell lymphoma (LBCL) and ALLO-316 for advanced or metastatic renal cell carcinoma (RCC). Allogene operates primarily in the United States, with its headquarters and research facilities located in South San Francisco, California. As a clinical-stage entity, the company does not yet generate commercial product revenue and relies on funding from public offerings, partnerships, and grants to finance its research and development activities. Its competitive position is defined by its proprietary technologies, including the Dagger platform, and strategic licenses from partners like Cellectis and Servier, positioning it as a pioneer in the next generation of allogeneic cell therapies.
